Sagimet Biosciences Inc - Series A — Cash Flow (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities -23.77 M-42.44 M-45.65 M -45.65 M Cash from investing activities 12.58 M-61.68 M4.56 M 4.56 M Cash from financing activities 86.17 M104.82 M275 K — Free cash flow -23.77 M-42.44 M-45.65 M -45.65 M

Nouvelles

Citizens réitère sa recommandation sur Sagimet Biosciences après les progrès MASH

Citizens reiterates Sagimet Biosciences stock rating on MASH progress

Oppenheimer réitère sa recommandation sur Sagimet après les progrès de l’essai MASH

Oppenheimer reiterates Sagimet stock rating on MASH trial progress

L’action Sagimet en hausse après des données de sécurité positives pour son médicament contre l’acné

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Le président exécutif de Sagimet Biosciences vend des actions pour 290.000€

Sagimet Biosciences executive chairman sells $290k in shares